Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033384 · ClinicalTrials.gov registry record · Phase 2
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00033384 is a Phase 2 study that has completed, run by University of Alabama at Birmingham.
The verdict
NCT00033384, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.
Interventions
- DRUG CI-1040
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-02 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033384
The ClinicalTrials.gov registry entry for NCT00033384 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CI-1040 is the first listed.
NCT00033384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033384 about?
NCT00033384 is a clinical study titled "CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer". RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non...
What is the current status of trial NCT00033384?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-02. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00033384?
The interventions under investigation include: CI-1040 (DRUG).
Who is sponsoring clinical trial NCT00033384?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.